The Global Burden of Deep Vein Thrombosis (DVT): Epidemiology and Statistics
**Disclaimer:** This article is intended for informational and scientific purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Introduction
Deep Vein Thrombosis (DVT) is a serious medical condition characterized by the formation of a blood clot, most commonly in the deep veins of the leg, but it can also occur in other parts of the body. Together with Pulmonary Embolism (PE), where a part of the clot breaks off and travels to the lungs, DVT forms part of a broader condition known as Venous Thromboembolism (VTE). VTE represents a significant global health challenge, contributing substantially to morbidity and mortality worldwide [1]. This comprehensive overview delves into the epidemiology and statistics of DVT, highlighting its global burden, key risk factors, and the critical need for increased awareness and effective management strategies.
Epidemiology of DVT and VTE
Incidence and Prevalence
The global incidence and prevalence of DVT and VTE vary significantly across different populations and geographical regions. In Western countries, the annual incidence rates for VTE, DVT, and PE are estimated at 150, 90, and 67 per 100,000 population, respectively [2]. However, reported VTE incidences are considerably lower in East Asia, suggesting potential genetic, environmental, or diagnostic differences [2].
In the United States, as many as 900,000 people could be affected by VTE each year [3]. DVT and PE account for approximately 51% and 49% of VTE cases, respectively, with variations observed based on age, sex, ethnicity, and race [4]. The incidence of VTE generally increases with age, and while it is comparable between sexes, men may exhibit a higher risk of recurrence [2].
Mortality Rates
VTE is a major contributor to global mortality, responsible for 1 in 4 deaths worldwide [5]. PE, in particular, is a leading cause of vascular death after heart attack and stroke [5]. An estimated 60,000–100,000 Americans die of VTE each year [3]. Globally, the PE-related mortality rate has shown a decline over the last two decades, decreasing from 3.49 per 100,000 in 2001 to 2.42 per 100,000 in 2023 [6]. This decline is more pronounced in high-income countries, particularly in European regions, where age-standardized mortality rates significantly reduced [6]. Conversely, lower-to middle-income countries have shown a rising trend in PE-related mortality, indicating persistent disparities in healthcare access and management [6].
It is estimated that death from PE, including sudden death from undiagnosed, untreated PE, may be responsible for approximately 3% of all deaths [2]. Even with conservative calculations, the VTE death rate is approximately 26 per 100,000, making it the third most common cause of death from cardiovascular diseases and the fifth from all causes in Europe and North America [2].
Key Risk Factors
Several factors significantly increase an individual's risk of developing DVT and VTE. Understanding these risk factors is crucial for effective prevention and early intervention.
Hospitalization and Surgery
Hospitalization, especially with or without surgery, is a major risk factor for VTE. More than a third of VTE cases diagnosed annually are related to a recent hospitalization, with many occurring after discharge [3]. VTE is a leading cause of preventable hospital death in the United States and the fifth most frequent reason for unplanned hospital readmissions after surgery [3]. Prophylactic measures, such as anticoagulant medications or compression stockings, can prevent up to 70% of healthcare-associated VTE cases, yet these measures are often underutilized [3].
Cancer
Cancer and its treatment are strongly associated with an increased risk of VTE. Approximately one in five VTE cases are cancer-related, with the highest risk observed in the initial months following a cancer diagnosis when treatment is typically initiated [3]. Patients with cancer who also develop VTE have lower survival rates [3].
Pregnancy
Pregnancy and the postpartum period significantly elevate the risk of VTE. Women are five times more likely to experience VTE during pregnancy, childbirth, or the three-month period following delivery [3]. PE is one of the most common causes of pregnancy-related death in the United States [3].
Other Factors
Other notable risk factors include:
- **Obesity:** Presents the highest risk among several factors, with a globally ascendant slope [7].
- **Thrombophilia:** Genetic predispositions like Factor V Leiden or protein C deficiency are well-documented correlations with thromboembolism [4].
- **Previous VTE:** A history of DVT or PE significantly increases the risk of recurrence [4].
- **Cardiac Dysrhythmias:** Conditions like atrial fibrillation are associated with a higher prevalence of VTE [4].
- **Chronic and Acute Renal Failure:** Both are recognized as independent risk factors for DVT and PE [4].
- **Smoking:** Increases a person's risk of thromboembolism by 17% [4].
Impact and Complications
The consequences of DVT and VTE extend beyond the acute event, leading to significant long-term complications and impacting patients' quality of life.
Recurrence
One-third of individuals who experience a VTE will have a recurrence within 10 years [3]. Recurrence itself contributes to morbidity and mortality, with rates approaching 30% at 10 years without extended anticoagulation [2].
Post-Thrombotic Syndrome (PTS)
Between one-third and one-half of individuals who have had a DVT will develop long-term complications such as post-thrombotic syndrome (PTS). PTS manifests as chronic swelling, pain, discoloration, and scaling in the affected limb, significantly impairing daily activities and quality of life [3].
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
CTEPH is a severe complication that can occur after a PE, particularly with large clots. It results from incomplete resolution of pulmonary emboli, leading to persistent obstruction and increased pressure in the pulmonary arteries, which can be fatal [3].
Addressing the Burden
Reducing the global burden of DVT and VTE requires a multi-faceted approach focusing on awareness, risk assessment, and effective prophylaxis.
Increasing VTE Awareness
Enhancing public and healthcare professional awareness of VTE, its risk factors, and treatment options is paramount. Initiatives like World Thrombosis Day, sponsored by the International Society on Thrombosis and Haemostasis, play a crucial role in educating the public and fostering early recognition and intervention [5].
VTE Risk Assessment
Systematic VTE risk assessment in hospitalized patients is essential for identifying individuals at high risk and implementing appropriate preventive measures. Despite guidelines, thromboprophylaxis remains underutilized in many clinical settings [5].
Appropriate Use of Thromboprophylaxis
The judicious use of thromboprophylaxis, including mechanical devices and pharmacologic anticoagulants, is critical for preventing VTE, especially in high-risk populations such as surgical patients and those with cancer. Balancing the benefits of prophylaxis with the risk of bleeding complications is a key clinical consideration [4].
Conclusion
Deep Vein Thrombosis and Venous Thromboembolism represent a substantial global health burden, characterized by significant incidence, prevalence, and mortality rates. The epidemiology of DVT is complex, influenced by a myriad of factors including age, geographical location, hospitalization, surgery, cancer, and pregnancy. The long-term complications, such as PTS and CTEPH, further underscore the need for robust preventive strategies and improved management. Continued efforts in increasing awareness, implementing comprehensive risk assessment protocols, and optimizing thromboprophylaxis are vital to mitigate the impact of DVT and improve patient outcomes worldwide.
References
[1] Wendelboe, A., & Weitz, J. I. (2024). Global Health Burden of Venous Thromboembolism. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 44(5), 1007-1011. [https://www.ahajournals.org/doi/10.1161/ATVBAHA.124.320151](https://www.ahajournals.org/doi/10.1161/ATVBAHA.124.320151) [2] Marschang, P., Gerotziafas, G., Kozak, M., Cosmi, B., Catalano, M., & Stanek, A. (2025). Epidemiology of venous thromboembolism: implications for clinical practice. *Polish Archives of Internal Medicine*, 135(10). [https://www.mp.pl/paim/issue/article/17105/](https://www.mp.pl/paim/issue/article/17105/) [3] Centers for Disease Control and Prevention. (2025, January 27). *Data and Statistics on Venous Thromboembolism*. [https://www.cdc.gov/blood-clots/data-research/facts-stats/index.html](https://www.cdc.gov/blood-clots/data-research/facts-stats/index.html) [4] Cowan, S., Ghayyad, K., Conlon, M. J., Naik, M., Zeini, I., Hawks, M., ... & Kachooei, A. R. (2024). Trends in the Epidemiology of Deep Vein Thrombosis and Pulmonary Embolism in Patients Undergoing Surgery. *Cureus*, 16(12), e74925. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11687993/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11687993/) [5] World Thrombosis Day. (2024, April 24). *New paper explores the global health burden of thrombosis with focus on venous thromboembolism*. [https://www.worldthrombosisday.org/new-paper-explores-the-global-health-burden-of-thrombosis-with-focus-on-venous-thromboembolism/](https://www.worldthrombosisday.org/new-paper-explores-the-global-health-burden-of-thrombosis-with-focus-on-venous-thromboembolism/) [6] Hagiya, H., Harada, K., Nishimura, Y., Yamamoto, M., Nishimura, S., Yamamoto, M., ... & Koyama, T. (2025). Global trends in mortality related to pulmonary embolism: an epidemiological analysis of data from the World Health Organization mortality database from 2001 to 2023. *eClinicalMedicine*, 86, 103389. [https://www.sciencedirect.com/science/article/pii/S2589537025003219](https://www.sciencedirect.com/science/article/pii/S2589537025003219) [7] Filip, C., Popa, C., & Popa, A. (2024). The Burden of Deep Vein Thrombosis and Risk Factors. *Medicina*, 60(3), 490. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11355405/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11355405/)